TransMedics (TMDX) CCO granted stock options and 11,082 RSUs

Rhea-AI Filing Summary

TransMedics Group, Inc. Chief Commercial Officer Giovanni Cecere reported equity awards consisting of stock options and restricted stock units. He was granted options to purchase 16,734 shares of common stock at an exercise price of $0.00 per share and 11,082 restricted stock units, each representing one share of common stock.

The option award vests as to 25% of the underlying shares on February 18, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. The RSU grant reflects additional direct equity-based compensation tied to the company’s stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Cecere Giovanni

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,734	$0.00	--
Grant/Award	Common Stock	11,082	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 16,734 shares (Direct); Common Stock — 19,057 shares (Direct)

Footnotes (1)

1. Consists of 11,082 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The option vests as to 25% of the shares underlying the option on February 18, 2027 and as to the remaining shares in equal monthly installments over three years thereafter, subject to continued service.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/20/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cecere Giovanni

(Last) (First) (Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER MA 01810

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		A		11,082(1)	A	$0	19,057	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$135.5	02/18/2026		A		16,734		(2)	02/18/2036	Common Stock	16,734	$0	16,734	D

Explanation of Responses:

1. Consists of 11,082 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. The option vests as to 25% of the shares underlying the option on February 18, 2027 and as to the remaining shares in equal monthly installments over three years thereafter, subject to continued service.

	By: /s/ Gerardo Hernandez, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did TransMedics (TMDX) report for Giovanni Cecere?

TransMedics reported that Chief Commercial Officer Giovanni Cecere acquired equity awards. He received options for 16,734 shares at an exercise price of $0.00 and 11,082 restricted stock units, each representing one share of common stock, as part of his equity compensation.

How many restricted stock units did Giovanni Cecere receive from TransMedics (TMDX)?

Giovanni Cecere received 11,082 restricted stock units. Each RSU represents a contingent right to receive one share of TransMedics’ common stock, linking part of his compensation directly to the company’s share value over time as the units vest.

What is the vesting schedule for Giovanni Cecere’s new stock options at TransMedics (TMDX)?

The option grant vests 25% of the underlying 16,734 shares on February 18, 2027. The remaining shares then vest in equal monthly installments over the next three years, subject to Mr. Cecere’s continued service with TransMedics.

Are Giovanni Cecere’s new TransMedics (TMDX) equity awards direct holdings?

Yes, the reported equity awards are categorized as directly owned. Both the 16,734 stock options and the 11,082 restricted stock units are listed with direct ownership, meaning they are attributed personally to Giovanni Cecere rather than to an external entity.

Does the TransMedics (TMDX) Form 4 show any stock sales by Giovanni Cecere?

The Form 4 shows only acquisitions through grants and awards, with no sales reported. Both transactions are coded as awards (code A), indicating grants of options and restricted stock units rather than any disposition or sale of existing TransMedics shares.

What does transaction code "A" mean in the TransMedics (TMDX) Form 4 for Giovanni Cecere?

Transaction code “A” indicates a grant, award, or other acquisition of securities. In this case, it reflects the award of 16,734 stock options and 11,082 restricted stock units to Giovanni Cecere as part of his equity-based compensation package.